Cilostazol Tablets
Function and Efficacy
This product is an antiplatelet drug. It inhibits the activity of phosphodiesterase in platelets and vascular smooth muscle, thereby increasing the cAMP concentration in platelets and smooth muscle, exerting antiplatelet and vasodilatory effects. This product inhibits the initial and secondary aggregation and release reactions of platelets induced by ADP, adrenaline, collagen and arachidonic acid, and is dose-dependent. Oral administration of 100 mg of cilostazol is 7 to 78 times more effective than the corresponding amount of aspirin in inhibiting platelet aggregation in vitro (aspirin is ineffective against initial platelet aggregation). This product does not interfere with the synthesis of vascular protective prostacyclin by vascular endothelial cells. For patients with chronic arterial occlusion, the use of volume plethysmography shows that this product can increase tissue blood flow in the foot and gastrocnemius muscles, increase the blood pressure index of the lower limbs, increase skin blood flow and increase skin temperature of the limbs, and improve intermittent claudication.
Ingredients
The main ingredient of this product is cilostazol, its chemical name is: 6-[4-(1-cyclohexyl-1H pentylenetetrazolium (5,) butoxy) 3,4-dihydro-1H-quinolone (2,) molecular formula: C20H27N5O2 molecular weight: 369.47
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| CilostazolIngredients |
This product is an antiplatelet drug. It inhibits the activity of phosphodiesterase in platelets and vascular smooth muscle, thereby increasing the cAMP concentration in platelets and smooth muscle, exerting antiplatelet and vasodilatory effects. This product inhibits the initial and secondary aggregation and release reactions of platelets induced by ADP, adrenaline, collagen and arachidonic acid, and is dose-dependent. Oral administration of 100 mg of cilostazol is 7 to 78 times more effective than the corresponding amount of aspirin in inhibiting platelet aggregation in vitro (aspirin is ineffective against initial platelet aggregation). This product does not interfere with the synthesis of vascular protective prostacyclin by vascular endothelial cells. For patients with chronic arterial occlusion, the use of volume plethysmography shows that this product can increase tissue blood flow in the foot and gastrocnemius muscles, increase the blood pressure index of the lower limbs, increase skin blood flow and increase skin temperature of the limbs, and improve intermittent claudication. More |
73963-72-1 | 30 |
Indication
It can inhibit platelet aggregation and has antithrombotic effect. It is used to treat local diseases such as chronic arterial occlusive ulcers, pain and cold sensation.
Usage and Dosage
Oral: Adults, 50-100 mg at a time, twice a day. For young patients, the dose can be increased appropriately if necessary based on symptoms.
Adverse Reactions
1. The main adverse reactions are headache, dizziness and palpitations caused by vasodilation, and some patients may experience high blood pressure; 2. The second are digestive tract symptoms such as abdominal distension, nausea, vomiting, stomach discomfort, abdominal pain, etc.; 3. A small number of patients developed abnormal liver function, frequent urination, abnormal urea nitrogen, creatinine and uric acid levels after taking the medicine; 4. Allergic symptoms include rash and itching; 5. There are occasional reports of leukopenia, subcutaneous hemorrhage, gastrointestinal bleeding, nosebleed, hematuria, fundus hemorrhage, etc.
Precautions
Patients with bleeding disorders (such as hemophilia, capillary fragility, active peptic ulcer, hematuria, hemoptysis, functional uterine bleeding, etc. or other bleeding tendencies).
Drug Interactions
Prostaglandin E1 can act synergistically with this product to increase intracellular cyclic adenosine monophosphate and enhance therapeutic efficacy.
Storage
Keep tightly closed.
Packaging Specification
50mg
Manufacturer
Jiangsu Xinhaikang Pharmaceutical Co., Ltd.
-
Founded in:
1990-09-18 -
Address:
No. 16 Changxing Road, Gaoyou City -
Tax NO.:
913210841409604419 -
Registered Funds:
23.5 million yuan -
Website:
-
Email: